New applications of gemcitabine and future directions in the management of pancreatic cancer

Cancer

Volumn 95, Issue 4 SUPPL., 2002, Pages 941-945

  Abbruzzese, James L ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Carcinogenesis; Gemcitabine; Pancreatic cancer; Phase II study; Survival

Indexed keywords

DEOXYCYTIDINE KINASE; GEMCITABINE; TRANSCRIPTION FACTOR;

ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURGERY; CARCINOGENESIS; CLINICAL TRIAL; CONFERENCE PAPER; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG RESPONSE; GRANULOCYTOPENIA; HUMAN; LEUKOPENIA; PANCREAS CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RADIOSENSITIVITY; SIGNAL TRANSDUCTION; SURVIVAL RATE; THROMBOCYTOPENIA;

EID: 0037103069     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.10753     Document Type: Conference Paper

References (17)

1. Cancer statistics, 1997
2. Gemcitabine: Progress in the treatment of pancreatic cancer
3. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial
4. Randomized phase II trial of dose intense gemcitabine by standard infusion vs. fixed dose rate in metastatic pancreatic adenocarcinoma
5. Phase I trial of gemcitabine combined with radiation for the treatment of locally advanced pancreatic adenocarcinoma
6. Action of 2′,2′-difluorodeoxycytidine on DNA synthesis
7. Cellular elimination of 2′,2′-difluorodeoxycytidine 5′-triphosphate: A mechanism of self-potentiation
8. Phase I trial of radiation (RT) concurrent with low-dose gemcitabine (GEM) for head and neck cancer: High mucosal and pharyngeal toxicity
9. A phase II study combining gemcitabine with radiotherapy in stage III NSCLC
10. On the development of gemcitabine-based chemoradiotherapy regimens in pancreatic cancer
11. A phase I study of gemcitabine (GEM) in combination with radiation therapy (RT) in patients with localized, unresectable pancreatic cancer
12. Phase I trial of twice-weekly gemcitabine and concurrent radiation in patients with advanced pancreatic cancer
13. Cancer and Leukemia Group B (CALGB) 89805: Phase II chemoradiation trial using gemcitabine in patients with locoregional adenocarcinoma of the pancreas
14. The nuclear factor-κB ReLA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells
15. Overexpression of urokinase-type plasminogen activator in pancreatic adenocarcinoma is regulated by constitutively activated ReLA
16. Cooperation between transcription factor AP-1 and NF-κB in the induction of interleukin-8 in human pancreatic adenocarcinoma cells by hypoxia
17. Molecular regulation of constitutive expression of interleukin-8 in human pancreatic adenocarcinona